Parallel Imports or Imposters: The Economics of Reimportation and Counterfeit Pharmaceuticals

REFERENCES

• Harris G. Pfizer moves to stem Canadian drug imports. New York Times. 2003 Aug 7.
   Google Scholar
• Ganslandt M, Maskus KE. Parallel imports of pharmaceutical products in the European Union. Policy Research Working Paper No. 2630. Washington, DC: The World Bank, Development Research Group, Trade; July 2001.
   Google Scholar
• DeKieffer D. The Mexican drug connection: How trade in pharmaceuticals has wrecked the FDA. Southwestern J Law Trade Americas. 2003; 9(2):321–30.
   Google Scholar
• Freeman R. Cross-border trade: One manufacturer's perspective. Paper pre-sented at University of Toronto and University of Michigan symposium, Cross-Border Internet Pharmacy: Public Policy Implications, Toronto, Canada; 2004 Mar 9.
   Google Scholar
• Bale HE. The conflicts between parallel trade and product access and innova-tion: The case of pharmaceuticals. J Int Econ Law. 1998; 1:637–54.
   Google Scholar
• Owcharenko N. Missing the point of Medicare reform: Why drug reimportation is bad policy. The Heritage Foundation. WebMemo #304. 2003 June 26. www.heritage. org/Research/HealthCare/wm304.cfm.
   Google Scholar
• World Health Organization. Counterfeit drugs: Report of a WHO/IFPMA workshop. WHO/DMP/CFD/92. Geneva: World Health Organization; 1992 Apr 1–3.
   Google Scholar
• DeKieffer D. The counterfeit-diversion link. In: LePark M, ed. Protecting medi-cines and pharmaceuticals: A manual of anticounterfeiting solutions. Greenwood Vil-lage, CO: Reconnaissance International; 2002:17–20.
   Google Scholar
• World Health Organization. Division of Drug Management & Policies and Ac-tion Programme on Essential Drugs. Counterfeit Drugs: Report of the International Workshop on Counterfeit Drugs. WHO/DRS/CFD/98.1. Geneva: World Health Orga-nization; 1997 Nov 26–28.
   Google Scholar
• Can G. Survey: The pharmaceutical industry. Economist. 1998; 346(8056): S 1–S 18.
   Google Scholar
• ten Ham M. Counterfeit drugs: Implications for health. Adverse Drug Reaction Toxicol Rev. 1992; 11(1):59–65.
   Google Scholar
• McGregor A. Counterfeit drugs flood developing world. Lancet. 1997; 350:1690.
   Google Scholar
• Associated Press. Drug wholesalers are indicted for selling fake, diluted drugs. Wall Street J [serial online]. 2003 Jul 22. online.wsj.com/article_print/0„SB1058834 64864828800,00.html.
   Google Scholar
• Knox R. Counterfeit drugs. NPR News, broadcast transcript; 2003 Jul 29.
   Google Scholar
• Christian J. Continuing concerns over imported pharmaceuticals. Prepared wit-ness testimony before the US House of Representatives, House Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. 2001 June 7. energycommerce.house.gov/107/hearings/06072001Hearing267/Christian404.htm.
   Google Scholar
• Hajari N. Swallowing bitter pills. Time. 1998; 151(Jan 26):261–70.
   Google Scholar
• Aaron H. The China syndrome. CDS Asia-Case Studies. www.cdsag.org/ cases_14.html.
   Google Scholar
• Datta PTJ. India turning capital for counterfeit drugs. Financial Times-The Business Line (India) [serial online]. 2003 Aug 3. search.ft.com/search/article.html?id = 030803002489.
   Google Scholar
• Tavis LA, Williams OF, eds. The pharmaceutical corporate presence in devel-oping countries. Notre Dame, IN: University of Notre Dame Press; 1993.
   Google Scholar
• Stipp D. Farewell, my logo. Fortune. 1996; 133(May 27):128–38.
   Google Scholar
• Schwab D. Drug firms, FDA come to grips with counterfeits. Star-Ledger. 2003 Sept 28.
   Google Scholar
• Saywell T, McManus J. What's in the pill? Far Eastern Econ Rev. 2002; 165(7):34–7.
   Google Scholar
• Goodman PS. China's big headache: Fake pharmaceuticals. Washington Post. 2002 Aug 30:A1.
   Google Scholar
• Pharmaceutical Research and Manufacturers of America. Pharmaceutical in-dustry profile 2003. www.phrma.org/publications/publications/profile02/index.cfm.
   Google Scholar
• O'Connor A. How consumers should check drugs. New York Times. 2003 Oct 3.
   Google Scholar
• Grady D. F.D.A. outlines plans to counter growing trade in counterfeit pharmaceuticals. New York Times. 2003 Oct 3.
   Google Scholar
• Crouch G. Europeans investigate resale of AIDS drugs. New York Times. 2003 Oct 29.
   Google Scholar
• Dingell JD. Excerpt from the Congressional Record of Congressman John D. Dingell's statement before the House of Representatives. H7597-H7598. 2003 Jul 24. www.house.gov/commerce_democrats/press/108st63.htm.
   Google Scholar
• Harris G. F.D.A. faults quality of imported drugs. New York Times. 2003 Sept 30.
   Google Scholar
• Danzon PM. The economics of parallel trade. PharmacoEconomics. 1998; 13:293–304.
   PubMed Web of Science ®Google Scholar
• Turner GM. Pay tomorrow for cheap drugs today. Galen Institute. 2003 Jul 28. www.galen.org/pdrugs.asp?docID=503.
   Google Scholar
• Calfee J. Why drugs from Canada won't cut prices. Consumers' Research. 2002; (Nov): 10–12. www.phrma.org/publications/policy/admin/2003-07-10.771.pdf.
   Google Scholar
• Reuters. Pfizer cutting off American seniors from medicines in Canada. Reuters. 2003; Aug 7. www.house.gov/larson/reimportnews.htm#2.
   Google Scholar
• Tufts Center for the Study of Drug Development. Total cost to develop a pre-scription drug, including cost of post-approval research, is $897 million. 2003 May 13. c sdd.tufts edu/NewsEvents/RecentNews. asp ?newsid=29.
   Google Scholar
• Levin RC, Klevorick AK, Nelson RR, Winter SG. Appropriating the returns from industrial research and development. Brookings Papers Econ Activity. 1987; 3:783–831.
   Google Scholar
• Cohen WM, Richard RN, Walsh J. A first look at the results of the 1994 Carne-gie Mellon Survey of Industrial R&D in the United States. Unpublished manuscript.
   Google Scholar
• Lybecker KM. Product piracy: The sale of counterfeit pharmaceuticals in devel-oping countries [dissertation]. Berkeley, CA: University of California, Berkeley; 2000.
   Google Scholar
• Pharmaceutical Research and Manufacturers of America. Insights 2003: High-lights from the pharmaceutical industry profile. www.phrma.org/publications/publica-tions/2003-10-07.892.pdf.
   Google Scholar
• Grabowski H, Vernon J. A new look at the returns and risks to pharmaceutical R&D. Manage Sci. 1990; 36:804–21.
   Web of Science ®Google Scholar
• Galen Institute. Charges and facts about America's pharmaceutical industry. 2003 Apr 11.
   Google Scholar
• Gury M. IMS reports 9 percent constant dollar growth in '03 global pharma sales. 2003 Mar 15. www.imshealth.comfims/portal/front/articleC/0,2777,6599_3665_ 45365325,00.html
   Google Scholar
• Turner GM. Illegal drug imports threaten consumers' health. Detroit News. 2003 May 11.
   Google Scholar